ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "rheumatoid arthritis (RA) and rheumatoid arthritis"

  • Abstract Number: 55 • 2019 ACR/ARP Annual Meeting

    A Novel Subclass of Intravascular Non-classical, Tissue Resident Synovial Monocyte Is Critical for Rheumatoid Arthritis Pathogenesis

    Anna Montgomery 1, Shang-Yang Chen 1, Deborah Winter 2 and Harris Perlman2, 1Northwestern University, Chicago, 2Northwestern University Feinberg School of Medicine, Division of Rheumatology, Chicago

    Background/Purpose: There are at least three populations of circulating monocytes; classical, intermediate and non-classical. We demonstrated that circulating non-classical monocytes are required for the effector…
  • Abstract Number: 1193 • 2019 ACR/ARP Annual Meeting

    EMR-integrated Disease Activity Calculators Improve Treatment to Target in Rheumatoid Arthritis

    Gabrielle Barbera1, Jasleen Kahlon 2, Manank Patel 3, Scott Pompa 4 and Arundathi Jayatilleke 1, 1Drexel, Philadelphia, PA, 2Hahnemann, Philadelphia, PA, 3Rutgers, New Brunswick, NJ, 4Dartmouth, Lebanon, NH

    Background/Purpose: Undertreatment of RA can lead to cumulative joint damage as well as negatively impact emotional health. Recent evidence favors a treat-to-target strategy to achieve…
  • Abstract Number: L06 • 2018 ACR/ARHP Annual Meeting

    Safety and Efficacy of Filgotinib in a Phase 3 Trial of Patients with Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Biologic Dmards

    Mark C. Genovese1, Kenneth C. Kalunian2, David Walker3, Jacques-Eric Gottenberg4, Kurt de Vlam5, Neelufar Mozaffarian6, Beatrix Bartok6, Franziska Matzkies6, Jie Gao6, Ying Guo6, Chantal Tasset7, John S. Sundy6 and Tsutomu Takeuchi8, 1Division of Immunology & Rheumatology, Stanford University, Stanford, CA, 2Division of Rheumatology, Allergy and Immunology, University of California, San Diego, La Jolla, CA, 3Northumbria Healthcare, United Kingdom, United Kingdom, 4Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, 5Department of Rheumatology, Universitair Ziekenhuis Leuven, Leuven, Belgium, 6Gilead Sciences, Inc., Foster City, CA, 7Galapagos NV, Mechelen, Belgium, Mechelen, Belgium, 8Division of Rheumatology, Keio University School of Medicine, Tokyo, Japan

    Background/Purpose: Filgotinib (FIL), an oral, selective, Janus Kinase 1 (JAK1) inhibitor was effective in phase 2 studies of active RA in patients (pts) with insufficient…
  • Abstract Number: 2035 • 2018 ACR/ARHP Annual Meeting

    Effect of Baricitinib on Joint-Related Biomarkers in Patients with Moderate-to-Severe Rheumatoid Arthritis

    Christian S. Thudium1, Anne C. Bay-Jensen1, Suntara Cahya2, Ernst R. Dow2, Morten A. Karsdal1, Alisa E. Koch2, Wenling Zhang2 and Robert J. Benschop2, 1Nordic Bioscience, Herlev, Denmark, 2Eli Lilly and Company, Indianapolis, IN

    Background/Purpose: Baricitinib (bari) is an oral selective inhibitor of Janus kinase (JAK) 1 and JAK2. In the phase 3 study RA-BUILD (NCT01721057), once-daily bari yielded…
  • Abstract Number: 2038 • 2018 ACR/ARHP Annual Meeting

    Subgroups By the Peripheral Immunophenotyping and Different Responses to Biological Dmards in Patients with Rheumatoid Arthritis

    Satoshi Kubo1, Shingo Nakayamada1, Yusuke Miyazaki1, Maiko Yoshikawa2, Hiroko Yoshinari3, Shigeru Iwata4, Kentaro Hanami2, Shunsuke Fukuyo3, Ippei Miyagawa5, Kazuhisa Nakano1 and Yoshiya Tanaka6, 1First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, 2The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, 3University of Occupational and Environmental Health, Japan, Fukuoka, Japan, 4First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, 5University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, 6University of Occupational and Environmental Health, Kitakyushu, Japan

    Background/Purpose: In the treatment of rheumatoid arthritis (RA), molecular targeted therapies induced different changes in different immune cell phenotypes. For instance, our previous study showed…
  • Abstract Number: 2551 • 2018 ACR/ARHP Annual Meeting

    Rheumatoid Arthritis Treatment with Filgotinib: Week 132 Safety Data from a Phase 2b Open-Label Extension Study

    Arthur Kavanaugh1, Mark C. Genovese2, Kevin Winthrop3, Maria Greenwald4, Lucia Ponce5, Favio Enriquez Sosa6, Mykola Stanislavchuk7, Minodora Mazur8, Alberto Spindler9, Regina Cseuz10, Natalya Nikulenkova11, Maria Glowacka-Kulesz12, Istvan Szombati13, Anna Dudek14, Neelufar Mozaffarian15, Joy Greer16, Rebecca Kunder15, Di An17, Luc Meuleners18, Robin Besuyen18, Rieke Alten19 and René Westhovens20, 1University of California, San Diego, School of Medicine, La Jolla, CA, 2Stanford University Medical Center, Palo Alto, CA, 3Oregon Health and Science University, Portland, OR, 4Desert Medical Advances, Palm Desert, CA, 5Cons. Priv. Temuco, Temuco, Chile, 6Clinstile SA de CV, Col., Mexico City, Mexico, 7Rheumatology, Vinnytsia Regional Clinical Hospital, Vinnytsia, Ukraine, 8IMSP Inst. de Cardiologie, Chisinau, Moldova, The Republic of, 9Centro Médico Privado de Reumatología, Centro Médico Privado de Reumatología, Argentina, 10Revita Reumatologiai Kft, Budapest, Hungary, 11Vladimir Reg Clin Hosp, Vladimir, Russian Federation, 12Silesiana Centrum Medyczne, Wroclawska, Poland, 13Qualiclinic Kft., Budapest, Hungary, 14AMED Medical Center, Warsaw, Poland, 15Gilead Sciences, Inc., Foster City, CA, 16Gilead Sciences, Inc, Foster City, CA, 17Gilead Science, Inc., Foster City, CA, 18Galapagos NV, Mechelen, Belgium, Mechelen, Belgium, 19Schlosspark-Klinik University Medicine, Berlin, Germany, 20Rheumatology, University Hospital KU Leuven, Leuven, Belgium

    Background/Purpose: The orally administered, selective inhibitor of Janus Kinase 1 (JAK1), filgotinib (FIL), is currently being investigated for the treatment of rheumatoid arthritis (RA) in…
  • Abstract Number: 2798 • 2018 ACR/ARHP Annual Meeting

    Expanded T-Cell Clones Are Present in the Synovium before the Clinical Onset of Rheumatoid Arthritis

    Giulia Balzaretti1,2,3, Paul L. Klarenbeek4, Marieke E. Doorenspleet5, Maria JH de Hair6, Barbera C.D. van Schaik7, Rebecca Esveldt2, Marleen van de Sande1, Danielle Gerlag8, Antoine H.C. van Kampen7, Frank Baas2,9, Paul-Peter Tak10 and Niek de Vries3,5, 1Clinical Immunology & Rheumatology, ARC | Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, 2Dept. of Genome Analysis, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, 3Dept. of Experimental Immunology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, 4Amsterdam Rheumatology & immunology Center | Department of Experimental Immunology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, 5Amsterdam Rheumatology and immunology Center | Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, 6Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, the Netherlands, Utrecht, Netherlands, 7Bioinformatics Laboratory, Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, 8GlaxoSmithKline, Stevenage, United Kingdom, 9Dept. of Genome Diagnostics, Leiden University, Leiden, Netherlands, 10GlaxoSmithKline, Cambridge, United Kingdom

    Background/Purpose: In healthy individuals with arthralgia and RA-specific autoantibodies (so called at-risk individuals) the presence of expanded B-cell receptor (BCR) clones in peripheral blood (PB)…
  • Abstract Number: 1327 • 2017 ACR/ARHP Annual Meeting

    Decreased Inflammatory Arthritis in Human Serum Paraoxonase 1 Transgenic Mice

    Christina Charles-Schoeman1, Ani Shahbazian2, Jennifer Wang3, Victor Grijalva4 and Srinivasa T. Reddy4, 1University of California, Los Angeles, Los Angeles, CA, 2Medicine-Rheumatology, University of California, Los Angeles, Los Angeles, CA, 3UCLA, Los Angeles, CA, 4Medicine-Cardiology, University of California, Los Angeles, Los Angeles, CA

    Background/Purpose: Paraoxonase 1 (PON1) is an HDL-associated protein, which hydrolyzes biologically active oxidized phospholipids and prevents oxidation of lipids in LDL and HDL. Increased lipid…
  • Abstract Number: 1401 • 2017 ACR/ARHP Annual Meeting

    Persistence of Mast Cell-Rich Synovitis Is Associated with Lack of Response to Synthetic Disease Modifying Anti-Rheumatic Drugs in Patients with Early Rheumatoid Arthritis

    Felice Rivellese, Frances Humby, Sara Pagani, Alessandra Nerviani and Costantino Pitzalis, Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts and The London, School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom

    Background/Purpose: Mast cells (MCs) are immune cells infiltrating the synovial membrane and implicated in the pathogenesis of Rheumatoid Arthritis, but their strict contribution to disease…
  • Abstract Number: 1477 • 2017 ACR/ARHP Annual Meeting

    Patient-Reported Outcomes As Independent Measures of Treatment Success with Sirukumab, an Anti-IL6 Cytokine Monoclonal Antibody, in Patients with Active Rheumatoid Arthritis: Post-Hoc Analysis of 2 Placebo-Controlled Phase 3 Trials

    Vibeke Strand1, Rita Ganguly2, Nan Li3, Prasheen Agarwal3, Shihong Sheng3, Kaiyin Fei3, Kelly McQuarrie3 and Sharon Popik3, 1Division of Immunology/Rheumatology, Stanford University, Stanford, CA, 2GlaxoSmithKline, Collegeville, PA, 3Janssen Research & Development, LLC, Spring House, PA

    Background/Purpose: Sirukumab, a selective, high-affinity, human anti–IL-6 monoclonal antibody, is in development for rheumatoid arthritis (RA) and other diseases.  Effects of sirukumab on RA symptoms…
  • Abstract Number: 1478 • 2017 ACR/ARHP Annual Meeting

    Inadequate Clinical Response to Sirukumab, an Anti-IL-6 Monoclonal Antibody, Can be Predicted after a Single Dose of Treatment in Patients with Rheumatoid Arthritis

    Shruti Daga1, Daniel Aletaha2, Benjamin Hsu3, Jennifer Gilbride4, Jacquie Christie5, Matthew Loza3, Bidisha Dasgupta3, Kim Campbell3, Kurt Brown6, Ravi Rao5 and Paul P. Tak5, 1GlaxoSmithKline, Uxbridge, United Kingdom, 2Department of Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, 3Janssen Research & Development, LLC, Spring House, PA, 4Sum of Squares Ltd, Hertfordshire, United Kingdom, 5GlaxoSmithKline, Stevenage, Hertfordshire, United Kingdom, 6GlaxoSmithKline, Collegeville, PA

    Background/Purpose: Response to therapy in rheumatoid arthritis (RA) is heterogeneous. Early identification of patients (pts) who are unlikely to achieve a meaningful clinical response may…
  • Abstract Number: 1908 • 2017 ACR/ARHP Annual Meeting

    Long-Term Efficacy and Safety Results of a Global Phase 3 Trial of Sirukumab, an Anti–IL-6 Cytokine Monoclonal Antibody, in Patients with Active Rheumatoid Arthritis Despite Disease-Modifying Anti-Rheumatic Drug Treatment

    Carter Thorne1, Tsutomu Takeuchi2, George Karpouzas3, Shihong Sheng4, Regina Kurrasch5, Kaiyin Fei4 and Benjamin Hsu4, 1University of Toronto, Newmarket, ON, Canada, 2Keio University Hospital School of Medicine, Tokyo, Japan, 3Division of Rheumatology, Harbor-UCLA Medical Center, Torrance, CA, 4Janssen Research & Development, LLC, Spring House, PA, 5GlaxoSmithKline, Collegeville, PA

    Background/Purpose: In patients (pts) with active rheumatoid arthritis (RA) despite DMARD treatment, sirukumab, a human monoclonal antibody that selectively binds to the IL-6 cytokine with…
  • Abstract Number: 2437 • 2017 ACR/ARHP Annual Meeting

    Long-Term Effect of Sirukumab, an Anti–IL-6 Cytokine Monoclonal Antibody, on Radiographic Progression in Patients with Active Rheumatoid Arthritis Despite Disease-Modifying Anti-Rheumatic Drug Treatment: Results of a Global Phase 3 Trial

    George Karpouzas1, Tsutomu Takeuchi2, Carter Thorne3, Shihong Sheng4, Regina Kurrasch5, Kaiyin Fei4 and Benjamin Hsu4, 1Division of Rheumatology, Harbor-UCLA Medical Center, Torrance, CA, 2Keio University School of Medicine, Tokyo, Japan, 3University of Toronto, Newmarket, ON, Canada, 4Janssen Research & Development, LLC, Spring House, PA, 5GlaxoSmithKline, Collegeville, PA

    Background/Purpose: In the SIRROUND-D study, sirukumab (SIR), a human monoclonal antibody that selectively binds to the IL-6 cytokine with high affinity, significantly reduced radiographic progression…
  • Abstract Number: 2472 • 2017 ACR/ARHP Annual Meeting

    Integrated Phase 3 Safety Results of Sirukumab, an Anti–IL-6 Cytokine Monoclonal Antibody, in Patients with Active Rheumatoid Arthritis

    Daniel Aletaha1, Carter Thorne2, Michael Schiff3, Masayoshi Harigai4, Prasheen Agarwal5, Ravi Rao6, Christopher Cohen7, Ben Cheng5, Kurt Brown7 and Benjamin Hsu5, 1Department of Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, 2University of Toronto, Newmarket, ON, Canada, 3University of Colorado School of Medicine, Aurora, CO, 4Division of Epidemiology and Pharmacoepidemiology of Rheumatic Diseases, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, 5Janssen Research & Development, LLC, Spring House, PA, 6GlaxoSmithKline, Stevenage, Hertfordshire, United Kingdom, 7GlaxoSmithKline, Collegeville, PA

    Background/Purpose: Sirukumab (SIR), a human monoclonal antibody that selectively binds to the IL-6 cytokine with high affinity, is in development for rheumatoid arthritis (RA) in…
  • Abstract Number: 2473 • 2017 ACR/ARHP Annual Meeting

    Sirukumab Subcutaneous Dose Regimens Maintain Clinical Response over Dosing Intervals in Rheumatoid Arthritis Patients: Results from a Phase 3 Study

    David M. Brooks1, Michael Plotnick2, Nicola J. Williams3, Regina Kurrasch1, Yanli Zhuang2, Debra J. Tompson3, Benjamin Hsu2 and Ravi Rao3, 1GlaxoSmithKline, Collegeville, PA, 2Janssen Research & Development, LLC, Spring House, PA, 3GlaxoSmithKline, Stevenage, Hertfordshire, United Kingdom

    Background/Purpose:   Sirukumab (SIR), a human monoclonal antibody that selectively binds to the IL-6 cytokine with high affinity, has demonstrated efficacy in rheumatoid arthritis (RA)…
  • 1
  • 2
  • 3
  • 4
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology